Achmea Innovation Fund sells stake in Stroke2prevent

Stroke2Prevent , active in the field of cardiac surgery, is going to spread its wings internationally. The company is supported by the medical wholesaler DeRoyal Healthcare from the United States. The Achmea Innovation Fund recently made it possible to register Stroke2prevent with the US Food and Drug Administration (FDA). Now that the company is entering its next phase, the Achmea Innovation Fund is transferring its equity interest of approximately 20% in Stroke2prevent to Medical2market Participaties.

Stroke2prevent supplies the so-called A-view, a medical device in the form of a balloon that has been developed to prevent strokes caused by cardiac surgery and cardiac aortic valve replacements. This tool can visualize arteriosclerosis in the aorta so that the medical team can use this information to determine the correct surgical strategy. This life-saving innovation reduces the risk of mortality in these operations by more than 30%. DeRoyal Healthcare is convinced that the A-view can have a global impact.

“We are pleased that we have contributed in recent years to the positive development of Stroke2prevent and thus to prevent deaths from heart surgery. We think that Medical2market Participaties and DeRoyal Healthcare are excellent parties to further expand the activities of Stroke2prevent and to put the A-view on the map worldwide.” – Ben Dijk, investment manager of Achmea Innovation Fund.

Achmea is the cooperative parent company of Centraal Beheer, Interpolis and Zilveren Kruis, among others.

The Achmea Innovation Fund focuses on promising, fast-growing startups and scaleups, often based on emerging technologies. The fund provides growth capital to promising companies that are active in Achmea’s strategic areas: health, mobility, housing and financial solutions for now, tomorrow and later.